Cel Sci Corp
CVM- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000725363
In the last 90 days, Cel Sci Corp insiders filed 1 open-market purchase and 0 sales; 40 institutions reported holding it in 13F filings for Q2 2026, worth $2.08M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Cel Sci Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $138.0K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$138.0K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Cel Sci Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Kersten Geert R | Chief Executive Officer | 316,142 | Aug 26, 2026 | 10 |
| Watson Robert Eugene | Director | 3,733 | Aug 17, 2026 | 1 |
| Baillavoine Bruno Jean-Marie | Director | 5,973 | Aug 17, 2026 | 1 |
| Cipriano John | Senior Vice President | – | Aug 17, 2026 | 1 |
| Talor Eyal | Chief Scientific Officer | 9,318 | Aug 17, 2026 | 5 |
| Prichep Patricia B | Chief Financial Officer | 17,489 | Aug 17, 2026 | 5 |
| Naughton Gail K | Director | – | Aug 10, 2023 | 0 |
| Young Peter R | Director | – | Aug 10, 2023 | 0 |
| Zimmerman Daniel H | Senior Vice President | 120,226 | Oct 3, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 26, 2026 (view filing)8:32 AM ET | Aug 25 | 1 day | Kersten Geert RChief Executive Officer | PPurchase | +100.0K | $1.38 | +$138.0K | +46.3%316.1K after | |
| May 18, 2026 (view filing) | May 14 | 4 days | Kersten Geert RChief Executive Officer | PPurchase | +300.0K | $1.20 | +$360.0K | +2,598.1%311.5K after | |
| May 14, 2026 (view filing) | May 13 | 1 day | Kersten Geert RChief Executive Officer | PPurchase | +100.0K | $1.19 | +$119.0K | +81.6%222.5K after | |
| Jan 26, 2026 (view filing) | Jan 22 | 4 days | Kersten Geert RChief Executive Officer | PPurchase | +38.0K | $5.26 | +$200.0K | +45.9%120.8K after | |
| Dec 5, 2025 (view filing) | Dec 4 | 1 day | Kersten Geert RChief Executive Officer | PPurchase | +8.39K | $5.96 | +$50.0K | +11.4%81.8K after | |
| Jul 29, 2025 (view filing) | Jul 25 | 4 days | Watson Robert EugeneDirector | PPurchase | +2.92K | $6.85 | +$20.0K | +358.6%3.73K after | |
| Jul 28, 2025 (view filing) | Jul 25 | 3 days | Kersten Geert RChief Executive Officer | PPurchase | +29.2K | $6.85 | +$200.0K | +66.9%72.8K after | |
| May 10, 2024 (view filing) | May 8 | 2 days | Watson Robert EugeneDirector | PPurchase | +20.0K | $1.39 | +$27.8K | +451.4%24.4K after | |
| May 9, 2024 (view filing) | May 8 | 1 day | Prichep Patricia BSenior Vice President | PPurchase | +8.00K | $1.39 | +$11.1K | +3.6%232.3K after | |
| May 9, 2024 (view filing) | May 8 | 1 day | Kersten Geert RChief Executive Officer | PPurchase | +30.0K | $1.39 | +$41.7K | +2.6%1.20M after | |
| Oct 21, 2021 (view filing) | Oct 19 | 2 days | Talor EyalChief Scientific Officer | SSale | −15.0K | $11.25 | −$168.8K | −12.5%104.9K after | |
| Jul 7, 2021 (view filing) | Jul 6 | 1 day | Watson Robert EugeneDirector | PPurchase | +1.25K | $8.00 | +$10.0K | +39.3%4.43K after | |
| Jul 7, 2021 (view filing) | Jul 6 | 1 day | Baillavoine Bruno Jean-MarieDirector | PPurchase | +1.25K | $8.00 | +$10.0K | +26.5%5.97K after | |
| Jul 7, 2021 (view filing) | Jul 6 | 1 day | Kersten Geert RChief Executive Officer | PPurchase | +25.0K | $8.00 | +$200.0K | +2.2%1.15M after |